Related Experiment Video
Updated: May 14, 2026
07:59
Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
ALK in lung cancer: past, present, and future
Alice T Shaw1, Jeffrey A Engelman
1Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA. ashaw1@partners.org
Summary
Anaplastic lymphoma kinase (ALK) gene rearrangements in non-small-cell lung cancer respond to targeted therapies like crizotinib. However, resistance develops, necessitating further research for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Anaplastic lymphoma kinase (ALK) gene rearrangements identified in a subset of non-small-cell lung cancers (NSCLC) in 2007.
- ALK-positive NSCLC exhibits high sensitivity to ALK kinase inhibitors, including crizotinib.
- Crizotinib demonstrated significant activity and clinical benefit in early-phase trials, leading to FDA approval in 2011.
Purpose of the Study:
- To review the history of ALK-positive lung cancer research.
- To discuss current diagnostic and treatment strategies for ALK-positive NSCLC.
- To identify future challenges and opportunities in managing ALK-positive lung cancers.
Main Methods:
- Literature review of ALK-positive non-small-cell lung cancer.
- Analysis of historical data on ALK inhibitors.
- Synthesis of current diagnostic and therapeutic approaches.
Main Results:
- ALK rearrangements are a key driver in a subset of NSCLC.
- ALK inhibitors like crizotinib provide substantial clinical benefit.
- Therapeutic resistance to ALK inhibitors is a significant clinical challenge.
Conclusions:
- ALK-targeted therapy has transformed outcomes for a subset of NSCLC patients.
- Overcoming resistance mechanisms is crucial for long-term disease control.
- Continued research is essential to improve survival and achieve cures for ALK-positive lung cancer.
